“The Food and Drug Administration (FDA) has surprised healthcare professionals when it recently announced the approval of both insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) 70/30. The FDA refused to approve Tresiba and Ryzodeg two years ago, citing concerns about the drugs’ adverse cardiovascular effects. However, in April 2015, the FDA began reviewing resubmitted applications for the treatments, which ultimately led to their approvals.
“Follow the money” says Diane Kress.
“I’m wondering what happened to the cardiovascular effects that kept these two insulins off the market two years ago. I notice there have been resubmitted applications, but the drugs are the same and they now have FDA approval. $$$ said Diane Kress”.
We already have high quality long acting insulins in Levimir and Lantus.
We already have high quality fast acting insulin in Novolog and Humalog
We already have quality 70/30 insulin in Novolin 70/30, Humulin 70/30, Novolog Mix 70/30, and Humalog Mix 75/25.
The market has plenty of long term/basal insulin, short term insulin, and mixed insulin. These new insulin’s had a glitch involving the heart and were not approved when they were submitted just two years ago. Why would we want to use it now? $$$ says Diane Kress.
PS….And just one question. Who wants a 42 hour insulin that is taken every 24 hours? Insulin overlap anyone? Thank you.